Efficacy and safety of minocycline in the treatment of intracerebral haemorrhage: study design and protocol for a multicentre, randomised, open-label, blinded endpoint clinical trial
European Stroke Journal · 2026
DOI: 10.1093/esj/aakag084 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift European Stroke Journal, 2026. Verfasst von Yang Qu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Stroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Minocycline, Cerebral Hemorrhage, Anti-Bacterial Agents, Neuroprotective Agents. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science and Technology Department of Jilin Province.
Abstract (Originalsprache)
Background
Although minocycline is a multi-target neuroprotective drug, its potential benefit in patients with ICH remains unclear. This study primarily aims to assess the efficacy and safety of minocycline for the treatment of ICH. Study design Efficacy and Safety of Minocycline in the Treatment of ICH (ENHANCE) is an ongoing prospective, multicentre, randomised, open-label, blinded-endpoint clinical trial. A total of 1248 patients with ICH within 24 h of onset will be randomly assigned to the minocycline or control group at a ratio of 1:1. The minocycline group will receive an initial dose of 200 mg minocycline hydrochloride capsules in addition to the guideline-based treatment, followed by 100 mg orally every 12 h for 7 days, resulting in a total of 14 administrations. The control group will receive only the guideline-based treatment. Study endpoints The primary efficacy outcome measure will be the proportion of patients with good functional outcomes (mRS score, 0–2) at 180 days. Safety outcome measures will include all adverse events and severe adverse events occurring during the study period. Summary The ENHANCE trial is designed to evaluate the effectiveness and safety of minocycline in the treatment of ICH.
Trial registration
Chinese Clinical Trials Registry identifier: ChiCTR2500114607.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
- Neuroscience Research Center, Department of Neurology, The First Hospital of Jilin University, Changchun, China.
ORCID-Profile: Yi Yang
Förderung
- Science and Technology Department of Jilin Province
Zitieren
APA
Qu, Y., Guo, Z. N., Qi, S., Abuduxukuer, R., Zhang, P., Li, H., Lv, X. N., Xu, Z. X., Yang, Y., & ENHANCE Protocol Steering Group (2026). Efficacy and safety of minocycline in the treatment of intracerebral haemorrhage: study design and protocol for a multicentre, randomised, open-label, blinded endpoint clinical trial. European Stroke Journal. https://doi.org/10.1093/esj/aakag084
Vancouver
Qu Y, Guo ZN, Qi S, Abuduxukuer R, Zhang P, Li H, et al. Efficacy and safety of minocycline in the treatment of intracerebral haemorrhage: study design and protocol for a multicentre, randomised, open-label, blinded endpoint clinical trial. European Stroke Journal. 2026. doi:10.1093/esj/aakag084
BibTeX
@article{Qu2026,
author = {Qu, Yang and Guo, Zhen-Ni and Qi, Shuang and Abuduxukuer, Reziya and Zhang, Peng and Li, Huimin and Lv, Xin-Ni and Xu, Zeng-Xin and Yang, Yi and ENHANCE Protocol Steering Group, ENHANCE Protocol Steering Group},
title = {Efficacy and safety of minocycline in the treatment of intracerebral haemorrhage: study design and protocol for a multicentre, randomised, open-label, blinded endpoint clinical trial},
journal = {European Stroke Journal},
year = {2026},
doi = {10.1093/esj/aakag084}
}
EUVIMED